Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2009 (2009), Article ID 616054, 12 pages
http://dx.doi.org/10.1155/2009/616054
Clinical Study

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function

1Department of Gastroenterology CA-2121, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
2Department of Medicine CA-2121, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
3Department of Anesthesia, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
4Department of Biomedical Sciences, The Panum Institute, Nørre Alle 20, DK-2200 Copenhagen, Denmark
5Department of Clinical Physiology and Nuclear Medicin, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Received 24 March 2009; Revised 22 June 2009; Accepted 25 June 2009

Academic Editor: Karel Geboes

Copyright © 2009 P. B. Jeppesen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Orskov, J. J. Holst, S. Knuhtsen, F. G. Baldissera, S. S. Poulsen, and O. V. Nielsen, “Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas,” Endocrinology, vol. 119, no. 4, pp. 1467–1475, 1986. View at Google Scholar
  2. M. Wojdemann, A. Wettergren, B. Hartmann, L. Hilsted, and J. J. Holst, “Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2513–2517, 1999. View at Google Scholar
  3. A. Bozkurt, E. Naslund, J. J. Holst, and P. M. Hellstrom, “GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat,” Regulatory Peptides, vol. 107, no. 1–3, pp. 129–135, 2002. View at Publisher · View at Google Scholar
  4. M. Wojdemann, A. Wettergren, B. Hartmann, and J. J. Holst, “Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs,” Scandinavian Journal of Gastroenterology, vol. 33, pp. 828–832, 1998. View at Google Scholar
  5. X. Guan, B. Stoll, X. Lu et al., “GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets,” Gastroenterology, vol. 125, no. 1, pp. 136–147, 2003. View at Publisher · View at Google Scholar
  6. D. J. Drucker, P. Ehrlich, S. L. Asa, and P. L. Brubaker, “Induction of intestinal epithelial proliferation by glucagon-like peptide 2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 15, pp. 7911–7916, 1996. View at Publisher · View at Google Scholar
  7. D. J. Drucker, L. DeForest, and P. L. Brubaker, “Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2,” American Journal of Physiology, vol. 273, no. 6, pp. G1252–G1262, 1997. View at Google Scholar
  8. D. A. Litvak, M. R. Hellmich, B. M. Evers, N. A. Banker, and C. M. Townsend Jr., “Glucagon-like peptide 2 is a potent growth factor for small intestine and colon,” Journal of Gastrointestinal Surgery, vol. 2, no. 2, pp. 146–150, 1998. View at Google Scholar
  9. C. Orskov, B. Hartmann, S. S. Poulsen, J. Thulesen, K. J. Hare, and J. J. Holst, “GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors,” Regulatory Peptides, vol. 124, no. 1–3, pp. 105–112, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. P. L. Brubaker, A. Izzo, M. Hill, and D. J. Drucker, “Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2,” American Journal of Physiology, vol. 272, no. 6, pp. E1050–E1058, 1997. View at Google Scholar
  11. C. I. Cheeseman and D. O'Neill, “Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2,” Experimental Physiology, vol. 83, no. 5, pp. 605–616, 1998. View at Google Scholar
  12. C. I. Cheeseman, “Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP- 2 infusion in vivo,” American Journal of Physiology, vol. 273, no. 6, pp. R1965–R1971, 1997. View at Google Scholar
  13. D. B. Henriksen, P. Alexandersen, B. Hartmann et al., “Disassociation of bone resorption and formation by GLP-2. A 14-day study in healthy postmenopausal women,” Bone, vol. 40, no. 3, pp. 723–729, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. L. Pironi, C. Zolezzi, E. Ruggeri, F. Paganelli, A. Pizzoferrato, and M. Miglioli, “Bone turnover in short-term and long-term home parenteral nutrition for benign disease,” Nutrition, vol. 16, no. 4, pp. 272–277, 2000. View at Publisher · View at Google Scholar
  15. P. B. Jeppesen, B. Hartmann, J. Thulesen et al., “Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon,” Gastroenterology, vol. 120, no. 4, pp. 806–815, 2001. View at Google Scholar
  16. P. B. Jeppesen, E. L. Sanguinetti, A. Buchman et al., “Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant qlucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients,” Gut, vol. 54, no. 9, pp. 1224–1231, 2005. View at Publisher · View at Google Scholar · View at PubMed
  17. K. V. Haderslev, P. B. Jeppesen, B. Hartmann et al., “Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon,” Scandinavian Journal of Gastroenterology, vol. 37, no. 4, pp. 392–398, 2002. View at Publisher · View at Google Scholar
  18. A. Schmassmann, H. F. Fehr, J. Locher et al., “Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans,” Gastroenterology, vol. 104, no. 4, pp. 1171–1181, 1993. View at Google Scholar
  19. A. Schmassmann, M. A. Angellotti, H. T. Ton-Nu et al., “Transport, metabolism, and effect of chronic feeding of cholylsarcosine, a conjugated bile acid resistant to deconjugation and dehydroxylation,” Gastroenterology, vol. 98, no. 1, pp. 163–174, 1990. View at Google Scholar
  20. S. Heydorn, P. B. Jeppesen, and P. B. Mortensen, “Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome,” Scandinavian Journal of Gastroenterology, vol. 34, no. 8, pp. 818–823, 1999. View at Publisher · View at Google Scholar
  21. P. B. Jeppesen and P. B. Mortensen, “Colonic digestion and absorption of energy from carbohydrates and medium-chain fat in small bowel failure,” Journal of Parenteral and Enteral Nutrition, vol. 23, no. 5, supplement, pp. S101–S105, 1999. View at Google Scholar
  22. P. B. Jeppesen, M. Staun, L. Tjellesen, and P. B. Mortensen, “Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection,” Gut, vol. 43, no. 6, pp. 763–769, 1998. View at Google Scholar
  23. C. Rosenquist, C. Fledelius, S. Christgau et al., “Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen,” Clinical Chemistry, vol. 44, no. 11, pp. 2281–2289, 1998. View at Google Scholar
  24. J. E. Cotes, D. J. Chinn, P. H. Quanjer, J. Roca, and J. C. Yernault, “Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society,” The European Respiratory Journal, vol. 16, pp. 41–52, 1993. View at Google Scholar
  25. P. H. Quanjer, G. J. Tammeling, J. E. Cotes, O. F. Pedersen, R. Peslin, and J. C. Yernault, “Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society,” The European Respiratory Journal, vol. 16, pp. 5–40, 1993. View at Google Scholar
  26. L. F. Black and R. E. Hyatt, “Maximal respiratory pressures: normal values and relationship to age and sex,” American Review of Respiratory Disease, vol. 99, no. 5, pp. 696–702, 1969. View at Google Scholar
  27. A. Ratkevicius and B. Quistorff, “Metabolic costs of force generation for constant-frequency and catchlike-inducing electrical stimulation in human tibialis anterior muscle,” Muscle and Nerve, vol. 25, no. 3, pp. 419–426, 2002. View at Publisher · View at Google Scholar · View at PubMed
  28. L. Johansen and B. Quistorff, “31P-MRS characterization of sprint and endurance trained athletes,” International Journal of Sports Medicine, vol. 24, no. 3, pp. 183–189, 2003. View at Publisher · View at Google Scholar · View at PubMed
  29. Y. Nakagawa, A. Ratkevicius, M. Mizuno, and B. Quistorff, “ATP economy of force maintenance in human tibialis anterior muscle,” Medicine and Science in Sports and Exercise, vol. 37, no. 6, pp. 937–943, 2005. View at Publisher · View at Google Scholar
  30. H. Galbo, M. Kjaer, and N. H. Secher, “Cardiovascular, ventilatory and catecholamine responses to maximal dynamic exercise in partially curarized man,” Journal of Physiology, vol. 389, pp. 557–568, 1987. View at Google Scholar
  31. L. W. J. Bogert and J. J. van Lieshout, “Non-invasive pulsatile arterial pressure and stroke volume changes from the human finger,” Experimental Physiology, vol. 90, no. 4, pp. 437–446, 2005. View at Publisher · View at Google Scholar · View at PubMed
  32. P. B. Jeppesen, P. Lund, I. B. Gottschalck et al., “Short bowel patients treated for two years with Glucagon-Like Peptide 2 (GLP-2): compliance, safety and effects on quality of life,” Gastroenterology Research and Practice, vol. 2009, 2009. View at Google Scholar
  33. M. Mizuno, A. Horn, N. H. Secher, and B. Quistorff, “Exercise-induced 31P-NMR metabolic response of human wrist flexor muscles during partial neuromuscular blockade,” American Journal of Physiology, vol. 267, no. 2, part 2, pp. R408–R414, 1994. View at Google Scholar
  34. H. I. Friedman, J. G. Chandler, C. C. Peck, T. J. Nemeth, and S. K. Odum, “Alterations in intestinal structure, fat absorption and body weight after intestinal bypass for morbid obesity,” Surgery Gynecology and Obstetrics, vol. 146, no. 5, pp. 757–767, 1978. View at Google Scholar
  35. M. H. Gleeson, S. R. Bloom, J. M. Polak, K. Henry, and R. H. Dowling, “Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function,” Gut, vol. 12, no. 10, pp. 773–782, 1971. View at Google Scholar
  36. F. M. Stevens, R. W. Flanagan, D. O'Gorman, and K. D. Buchanan, “Glucagonoma syndrome demonstrating giant duodenal villi,” Gut, vol. 25, no. 7, pp. 784–791, 1984. View at Google Scholar
  37. J. Thulesen, B. Hartmann, K. J. Hare et al., “Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice,” Gut, vol. 53, no. 8, pp. 1145–1150, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. A. Sylvan, B. Sjolund, K. G. Janunger, J. Rutegard, R. Stenling, and G. Roos, “Colorectal cancer risk after jejunoileal bypass: dysplasia and DNA content in longtime follow-up of patients operated on for morbid obesity,” Diseases of the Colon and Rectum, vol. 35, no. 3, pp. 245–248, 1992. View at Google Scholar
  39. M. Lauverjat, A. H. Aissa, P. Vanhems, P. Bouletreau, D. Fouque, and C. Chambrier, “Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition,” Clinical Nutrition, vol. 25, no. 1, pp. 75–81, 2006. View at Publisher · View at Google Scholar · View at PubMed